Targeting Enolase in Reducing Secondary Damage in Acute Spinal Cord Injury in Rats
- 231 Downloads
Spinal cord injury (SCI) is a complex debilitating condition leading to permanent life-long neurological deficits. The complexity of SCI suggests that a concerted multi-targeted therapeutic approach is warranted to optimally improve function. Damage to spinal cord is complicated by an increased detrimental response from secondary injury factors mediated by activated glial cells and infiltrating macrophages. While elevation of enolase especially neuron specific enolase (NSE) in glial and neuronal cells is believed to trigger inflammatory cascades in acute SCI, alteration of NSE and its subsequent effects in acute SCI remains unknown. This study measured NSE expression levels and key inflammatory mediators after acute SCI and investigated the role of ENOblock, a novel small molecule inhibitor of enolase, in a male Sprague–Dawley (SD) rat SCI model. Serum NSE levels as well as cytokines/chemokines and metabolic factors were evaluated in injured animals following treatment with vehicle alone or ENOblock using Discovery assay. Spinal cord samples were also analyzed for NSE and MMPs 2 and 9 as well as glial markers by Western blotting. The results indicated a significant decrease in serum inflammatory cytokines/chemokines and NSE, alterations of metabolic factors and expression of MMPs in spinal cord tissues after treatment with ENOblock (100 µg/kg, twice). These results support the hypothesis that activation of glial cells and inflammation status can be modulated by regulation of NSE expression and activity. Analysis of SCI tissue samples by immunohistochemistry confirmed that ENOblock decreased gliosis which may have occurred through reduction of elevated NSE in rats. Overall, elevation of NSE is deleterious as it promotes extracellular degradation and production of inflammatory cytokines/chemokines and metabolic factors which activates glia and damages neurons. Thus, reduction of NSE by ENOblock may have potential therapeutic implications in acute SCI.
KeywordsSpinal cord injury Enolase Glia Cytokines and chemokines Matrix metalloproteinases
This work was supported by grants from the South Carolina Spinal Cord Injury Research Fund (SCIRF 2015 P-01 and SCIRF #2016 I-03 to A. Haque), National Institutes of Health (R01 CA129560 to A. Haque), and the Veterans Administration (I01 BX001262 and I01 BX002349 to N. Banik). We thank Ms. Margaret Romano of Histology and Immunohistochemistry Laboratory at the Department of Pathology and Laboratory Medicine at MUSC for her technical assistance with the immunohistochemistry.
Compliance with Ethical Standards
Conflict of interest
The authors have no financial conflict of interest.
- 8.Bock A, Tucker N, Kelher MR, Khan SY, Gonzalez E, Wohlauer M et al (2015) Alpha-enolase causes proinflammatory activation of pulmonary microvascular endothelial cells and primes neutrophils through plasmin activation of protease-activated receptor 2. Shock 44(2):137–142. doi: 10.1097/SHK.0000000000000394 CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Sawhney S, Hood K, Shaw A, Braithwaite AW, Stubbs R, Hung NA et al (2015) Alpha-enolase is upregulated on the cell surface and responds to plasminogen activation in mice expressing a 133p53alpha mimic. PLoS ONE 10(2):e0116270. doi: 10.1371/journal.pone.0116270 CrossRefPubMedPubMedCentralGoogle Scholar
- 29.Bragge P, Piccenna L, Middleton J, Williams S, Creasey G, Dunlop S et al (2015) Developing a spinal cord injury research strategy using a structured process of evidence review and stakeholder dialogue. Part II: background to a research strategy. Spinal cord 53(10):721–728. doi: 10.1038/sc.2015.86 CrossRefPubMedGoogle Scholar
- 33.Lim JH, Muguet-Chanoit AC, Smith DT, Laber E, Olby NJ (2014) Potassium channel antagonists 4-aminopyridine and the T-butyl carbamate derivative of 4-aminopyridine improve hind limb function in chronically non-ambulatory dogs; a blinded, placebo-controlled trial. PLoS ONE 9(12):e116139. doi: 10.1371/journal.pone.0116139 CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Deng L, Ruan Y, Chen C, Frye CC, Xiong W, Jin X et al (2016) Characterization of dendritic morphology and neurotransmitter phenotype of thoracic descending propriospinal neurons after complete spinal cord transection and GDNF treatment. Exp Neurol 277:103–114. doi: 10.1016/j.expneurol.2015.12.018 CrossRefPubMedGoogle Scholar
- 42.Samantaray S, Das A, Matzelle DC, Yu SP, Wei L, Varma A et al (2016) Administration of low dose estrogen attenuates persistent inflammation, promotes angiogenesis, and improves locomotor function following chronic spinal cord injury in rats. J Neurochem 137(4):604–617. doi: 10.1111/jnc.13610 CrossRefPubMedPubMedCentralGoogle Scholar
- 49.Ray SK, Matzelle DD, Wilford GG, Hogan EL, Banik NL (2001) Inhibition of calpain-mediated apoptosis by E-64 d-reduced immediate early gene (IEG) expression and reactive astrogliosis in the lesion and penumbra following spinal cord injury in rats. Brain Res 916(1–2):115–126CrossRefPubMedGoogle Scholar
- 50.Kupina NC, Nath R, Bernath EE, Inoue J, Mitsuyoshi A, Yuen PW et al (2001) The novel calpain inhibitor SJA6017 improves functional outcome after delayed administration in a mouse model of diffuse brain injury. J Neurotrauma 18(11):1229–1240. doi: 10.1089/089771501317095269 CrossRefPubMedGoogle Scholar
- 51.Das A, Sribnick EA, Wingrave JM, Del Re AM, Woodward JJ, Appel SH et al (2005) Calpain activation in apoptosis of ventral spinal cord 4.1 (VSC4.1) motoneurons exposed to glutamate: calpain inhibition provides functional neuroprotection. J Neurosci Res 81(4):551–562. doi: 10.1002/jnr.20581 CrossRefPubMedGoogle Scholar
- 53.Zhao D, Amria S, Hossain A, Sundaram K, Komlosi P, Nagarkatti M et al (2011) Enhancement of HLA class II-restricted CD4 + T cell recognition of human melanoma cells following treatment with bryostatin-1. Cell Immunol 271(2):392–400. doi: 10.1016/j.cellimm.2011.08.007 CrossRefPubMedPubMedCentralGoogle Scholar
- 58.Goldstein OG, Hajiaghamohseni LM, Amria S, Sundaram K, Reddy SV, Haque A (2008) Gamma-IFN-inducible-lysosomal thiol reductase modulates acidic proteases and HLA class II antigen processing in melanoma. Cancer Immunol Immunother 57(10):1461–1470. doi: 10.1007/s00262-008-0483-8 CrossRefPubMedPubMedCentralGoogle Scholar
- 73.Pleines UE, Morganti-Kossmann MC, Rancan M, Joller H, Trentz O, Kossmann T (2001) S-100 beta reflects the extent of injury and outcome, whereas neuronal specific enolase is a better indicator of neuroinflammation in patients with severe traumatic brain injury. J Neurotrauma 18(5):491–498. doi: 10.1089/089771501300227297 CrossRefPubMedGoogle Scholar
- 77.Pfeifer R, Borner A, Krack A, Sigusch HH, Surber R, Figulla HR (2005) Outcome after cardiac arrest: predictive values and limitations of the neuroproteins neuron-specific enolase and protein S-100 and the Glasgow Coma Scale. Resuscitation 65(1):49–55. doi: 10.1016/j.resuscitation.2004.10.011 CrossRefPubMedGoogle Scholar
- 83.God JM, Zhao D, Cameron CA, Amria S, Bethard JR, Haque A (2014) Disruption of HLA class II antigen presentation in Burkitt lymphoma: implication of a 47,000 MW acid labile protein in CD4 + T cell recognition. Immunology 142(3):492–505. doi: 10.1111/imm.12281 CrossRefPubMedPubMedCentralGoogle Scholar